UCB SA (UCBJY) Discusses EADV Data Highlights and Long-Term Impact of BIMZELX in Dermatology Transcript

SA Transcripts 162.43K Followers Follow UCB SA ( UCBJY ) Discusses EADV Data Highlights and Long-Term Impact of BIMZELX in Dermatology October 1, 2026 8:30 AM EDT Company Participants Yvonne Naughton - Head of Investor Relations Emmanuel Caeymaex - Executive VP & Head of Patient Evidence Conference Call Participants Amit Garg Stacy Ku - TD Cowen, Research Division Henrietta Boeg - Deutsche Bank AG, Research Division Xian Deng - UBS Investment Bank, Research Division Kerry Holford - Joh. Berenberg, Gossler & Co. KG, Research Division James D. Wantling - JPMorgan Chase & Co, Research Division Rajan Sharma - Goldman Sachs Group, Inc., Research Division Presentation Yvonne Naughton Head of Investor Relations Hello, everyone, and welcome to UCB's EADV Capital Markets Call for Institutional Investors and Analysts. My name is Yvonne Naughton, and I lead the Investor Relations team here at UCB. Today's presentation is available for download on the Investor Relations section of our website. The presentation and Q&A session are subject to the disclaimer and safe harbor statement contained on Slide 2 of the presentation. On today's call, we will be discussing key takeaways from data being presented at the EADV Congress in Vienna, which supports the long-term impact of BIMZELX on tunnels and potential to prevent disease progression in hidradenitis suppurativa. Hosting our call today is UCB's Executive Vice President and Head of Patient Evidence, Emmanuel Caeymaex. And we're delighted to be joined by Dr. Amit Garg, Professor and Founding Chair for the Department of Dermatology, Northwell Health, New York. Following the presentations, we will open the line for questions. As usual, we will try to address as many questions as we can. So please limit your questions to allow others a fair chance to participate in the Q&A. And with that, I'll turn the call over to you, Emmanuel. Emmanuel Caeymaex Executive VP & Head of Patient Evidence Thank you